Imperial College London


Faculty of MedicineDepartment of Metabolism, Digestion and Reproduction

Professor of Hepatology. Head of Department



+44 (0)20 3312 1903m.thursz




Ms Dawn Campbell +44 (0)20 3312 6454




Norfolk PlaceSt Mary's Campus





Mark Thursz is professor of hepatology at Imperial College and consultant in hepatology at St Mary's Hospital, London. His clinical interests are in viral hepatitis, alcoholic liver disease and fatty liver disease. He is currently interested in developing programmes for treatment of chronic hepatitis B infection in resource poor settings to reduce the risk of hepatocellular carcinoma.

Professor Thursz' research interests are focussed on the natural history of viral hepatitis and fatty liver disease and the factors which determine chronic infection and progressive liver disease. He has a special interest in the genetic determinants of disease outcomes using genetic association and genome wide scanning to identify causative variants.

Professor Thursz is chief investigator on two multi-centre trials: The warfarin anticoagulation for liver fibrosis in patients transplanted for hepatitis C (WAFT-C) trial and the steroids or pentoxifylline for alcoholic hepatitis (STOPAH) trial.

Professor Thursz is a former secretary of the British Association for Study of the Liver (BASL) and is currently vice-secretary of the European Association for Study of the Liver. In this role he has special responsibility for EU policy and advocacy in Brussels.




Schröeder SE, Pedrana A, Scott N, et al., 2019, Innovative strategies for the elimination of viral hepatitis at a national level: A country case series., Liver Int, Vol:39, Pages:1818-1836

Mullish BH, McDonald JAK, Pechlivanis A, et al., 2019, Microbial bile salt hydrolases mediate the efficacy of faecal microbiota transplant in the treatment of recurrent Clostridioides difficile infection, Gut, Vol:68, ISSN:0017-5749, Pages:1791-1800

Bennett K, Enki DG, Thursz M, et al., 2019, Systematic review with meta-analysis: high mortality in patients with non-severe alcoholic hepatitis, Alimentary Pharmacology & Therapeutics, Vol:50, ISSN:0269-2813, Pages:249-257

Chambers E, Byrne C, Rugyendo A, et al., 2019, The effects of dietary supplementation with inulin and inulin-propionate ester on hepatic steatosis in adults with non-alcoholic fatty liver disease, Diabetes, Obesity and Metabolism, Vol:21, ISSN:1462-8902, Pages:372-376

Howell J, Atkinson SR, Pinato DJ, et al., 2019, Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma, European Journal of Cancer, Vol:116, ISSN:0959-8049, Pages:56-66

More Publications